The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Mozavaptan     N-[4-[(2-dimethylamino-6...

Synonyms: AGN-PC-0096MK, CHEMBL420762, cc-155, SureCN1649322, Opc-31260, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Opc 31260

  • OPC31260 treatment of cystic mice led to an amelioration of the cystic enlargement and azotemia [1].
  • When diet containing OPC31260 had been provided for 4 days until the day before the start of water loading, antidiuresis and hyponatremia (125.4 +/- 1.mEq/l) were significantly potentiated [2].
 

Psychiatry related information on Opc 31260

 

High impact information on Opc 31260

 

Gene context of Opc 31260

  • To determine if CD cAMP, generated from increased AVP-V2Rs, was accelerating the PKD, cystic mice and their normal littermates were treated with OPC31260, a relatively specific AVP-V2R antagonist [1].
  • V2R mRNA expression in kidney was significantly less in Tg rats than in control rats under basal conditions, and this suppression was restored by OPC31260 treatment to levels comparable with those of control rats [2].
 

Analytical, diagnostic and therapeutic context of Opc 31260

  • These results indicate that OPC31260 may be an effective treatment for these disorders and that clinical trials should be considered [5].

References

  1. Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Gattone, V.H., Maser, R.L., Tian, C., Rosenberg, J.M., Branden, M.G. Dev. Genet. (1999) [Pubmed]
  2. Adaptation to sustained high plasma vasopressin in water and electrolyte homeostasis in the rat transgenic for the metallothionein-vasopressin fusion gene. Yokoi, H., Nagasaki, H., Tachikawa, K., Arima, H., Murase, T., Miura, Y., Hirabayashi, M., Oiso, Y. J. Endocrinol. (2002) [Pubmed]
  3. Regulation of aquaporin mRNA expression in rat kidney by water intake. Murillo-Carretero, M.I., Ilundáin, A.A., Echevarria, M. J. Am. Soc. Nephrol. (1999) [Pubmed]
  4. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Torres, V.E., Wang, X., Qian, Q., Somlo, S., Harris, P.C., Gattone, V.H. Nat. Med. (2004) [Pubmed]
  5. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Gattone, V.H., Wang, X., Harris, P.C., Torres, V.E. Nat. Med. (2003) [Pubmed]
  6. Vasodilation induced by vasopressin V2 receptor stimulation in afferent arterioles. Tamaki, T., Kiyomoto, K., He, H., Tomohiro, A., Nishiyama, A., Aki, Y., Kimura, S., Abe, Y. Kidney Int. (1996) [Pubmed]
  7. Secretion of adrenomedullin by renal tubular cell lines. Sato, K., Imai, T., Iwashina, M., Marumo, F., Hirata, Y. Nephron (1998) [Pubmed]
 
WikiGenes - Universities